ANALYSIS OF THE TIME SPENT BY AIFA COMMITTEES FOR THE ASSESSMENT OF NEW DRUGS: IMPACT OF THE APPLICATION OF MANAGED ENTRY AGREEMENTS

被引：0
|
作者：
Brambilla, P. [1 ]
Torriani, A. [1 ]
Lidonnici, D. [1 ]
Ravasio, R. [1 ]
Raimondo, P. [1 ]
机构：
[1] MA Provider Srl, Milan, MI, Italy
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HPR160
引用
收藏
页码：S261 / S262
页数：2
相关论文
共 17 条
  • [1] THE IMPACT ON ACCESS TO INNOVATIVE DRUGS OF THE FIRST MANAGED ENTRY AGREEMENTS IN ROMANIA
    Chiriac, N. D.
    Radu, P. C.
    Pravat, M. A.
    VALUE IN HEALTH, 2016, 19 (07) : A503 - A503
  • [2] THE IMPACT OF MANAGED ENTRY AGREEMENTS ON DRUG TIME TO MARKET IN ITALY
    Urbinati, D.
    Rova, A.
    Mantuano, M.
    VALUE IN HEALTH, 2017, 20 (09) : A703 - A703
  • [3] A COMPARATIVE ANALYSIS ON APPLICATION OF MANAGED ENTRY AGREEMENTS (MEA) FOR ORPHAN DRUGS IN SELECTED EUROPEAN COUNTRIES
    Djambazov, S.
    Dacheva, A.
    Vutova, Y.
    Filipov, A.
    Vekov, T.
    VALUE IN HEALTH, 2020, 23 : S663 - S663
  • [4] THE BEHAVIOUR OF THE CANCER DRUGS FUND (CDF) OVER TIME; THE IMPACT OF INNOVATIVE THERAPIES AND IMPLICATIONS FOR MANAGED ENTRY AGREEMENTS
    MacDonald, D.
    Percival, C.
    O'Donnell, R.
    VALUE IN HEALTH, 2019, 22 : S493 - S493
  • [5] Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis
    Vreman, Rick
    Broekhoff, Thomas
    GM Leufkens, Hubert
    Mantel-Teeuwisse, Aukje
    Goettsch, Wim
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2020, 17 (22) : 1 - 20
  • [6] Managed Entry Agreements in the Context of Health Technology Assessment Recommendations in Ukraine: Analysis on the Stage of Development
    Khmelovska, M.
    Pinlazhko, O.
    Serediuk, O.
    Malyshevska, I
    Romanenko, I
    Babenko, M.
    Lobas, M.
    Kosyachenko, K.
    VALUE IN HEALTH, 2022, 25 (12) : S337 - S337
  • [7] THE FIRST MANAGED ENTRY AGREEMENTS BASED ON HEALTH TECHNOLOGY ASSESSMENT APPROVED IN UKRAINE: ANALYSIS AND FUTURE PERSPECTIVES
    Piniazhko, O.
    Khmelovska, M.
    Serediuk, V
    Malyshevska, I
    Romanenko, I
    Ioltukhovskyi, I.
    Masheiko, A.
    Babenko, M.
    Lobas, M.
    Kosyachenko, K.
    Kahveci, R.
    VALUE IN HEALTH, 2023, 26 (06) : S265 - S265
  • [8] The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment
    Sabine Elisabeth Grimm
    Mark Strong
    Alan Brennan
    Allan J. Wailoo
    PharmacoEconomics, 2017, 35 : 1287 - 1296
  • [9] The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment
    Grimm, Sabine Elisabeth
    Strong, Mark
    Brennan, Alan
    Wailoo, Allan J.
    PHARMACOECONOMICS, 2017, 35 (12) : 1287 - 1296
  • [10] Determinants of Managed Entry Agreements in the context of Health Technology Assessment: a comparative analysis of oncology therapies in four countries
    Efthymiadou, Olina
    Kanavos, Panos
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2021, 37 (01)
12